Ilaria S.
- Country
- Italy
- Department
- S.C. Oncologia Falck, Dipartimento Ematologia ed Oncologia
Research Overview
- Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine or Investigator's Choice Chemotherapy in Patients with FRα-High or FRα-Low Platinum-Resistant Epithelial Ovarian Cancer
- Efficacy and Safety Evaluation of Azenosertib (ZN-c3) in Recurrent or Persistent Uterine Serous Carcinoma: A Phase 2 Open-Label Multicenter Study
- Evaluation of Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-Type Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Data & Insights
Has run more than one trial at 118 of 281 partner sites.
Specializations
Gynecologic Oncology
This investigator specializes in treating complex gynecological cancers, with particular emphasis on high-grade serous ovarian cancer and related conditions affecting the fallopian tubes and peritoneum.
- Ovarian Cancer Management
- Peritoneal Cancer Treatment
- Fallopian Tube Malignancies
Their research explores innovative therapeutic approaches for patients with advanced gynecologic malignancies.
Endometrial Cancer Research
The investigator focuses on developing treatment strategies for advanced and recurrent endometrial cancer, with special attention to maintenance therapy approaches.
- Advanced Endometrial Cancer
- Recurrent Disease Management
- Maintenance Therapy Innovation
Their work encompasses evaluating novel therapeutic agents for endometrial cancer treatment.
Uterine Cancer Therapeutics
Specialized research in uterine serous carcinoma, particularly focusing on persistent and recurrent cases requiring advanced therapeutic intervention.
- Uterine Serous Carcinoma Treatment
- Recurrent Disease Therapy
- Novel Treatment Approaches
The investigator evaluates emerging treatments for aggressive forms of uterine cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.